Skip to main content

Table 3 Biotechnology companies working on the drugs against host targets and virus-host protein-protein interations

From: Virus-host interactomics: new insights and opportunities for antiviral drug discovery

Company Web site Location Viral application Stage Mode of action
Inhikibase Therapeutics www.inhibikase.com Atlanta (GA, USA) Polyomaviruses, HCV, HBV, smallpox virus, ebola virus, RSV, rhinovirus NC NC
Forge Life Science www.forgelifescience.com Doyleston (PA, USA) JCV, BKV, CMV, seasonal flu Research Enhances the innate role of human sirtuins
Ciclofilin Pharmaceuticals www.ciclofilin.com San Diego (CA, USA) HCV/HBV/HIV co-infection Preclinical Inhibitors of cyclophilin
Gemmus Pharma www.gemmuspharma.com San Francisco (CA, USA) FLUAV NC Agonist of a G protein-coupled receptor
Springbank Pharmaceuticals www.springbankpharm.com Milford (MA, USA) HCV and HBV Phase 1 Activates RIG1 and NOD2
iTherX www.itxpharma.com San Diego (CA, USA) HCV (liver transplant) Phase 1 Entry inhibitors
Prosetta Biosciences www.prosetta.com San Francisco (CA, USA) HCV, FLUAV, HIV1, RABV SAR Targets viral capsid host protein interaction
OyaGen Inc www.oyageninc.com Rochester (NY, USA) HIV1 Pre-clinical APOBEC3G activation and Vif-APOBEC3G interaction
Microbiotix www.microbiotix.com Worcester (MA, USA) Ebola virus Discovery Targets NPC1-glycoprotein interaction
Enyo Pharma www.enyopharma.com Lyon (France) HBV, FLUAV, Ebola virus Lead optimization NC
Scynexis www.scynexis.com Durham (NC, USA) HCV Phase 2 Inhibitors of cyclophilin
Vectura www.vectura.com Germany and UK Severe FLUAV Phase 2 Inhibitor of NF-κB
Novartis www.novartis.com Multinational HCV Phase 2 and 3 Cyclophilin A-NS5A interaction
  1. Abbreviations: BKV BK virus, HBV hepatitis B virus. HCV hepatitis C virus, CMV cytomegalovirus, FLUAV influenza A virus, JCV John Cunningham virus, NC not communicated; RABV, rabies virus; RSV, respiratory syncytial virus.